Caris Life Sciences, Inc. filings document financial results, governance matters, financing arrangements and material company events for an AI TechBio precision medicine business. Form 8-K disclosures report quarterly and annual operating results, molecular profiling services revenue, clinical therapy selection activity, and Regulation FD updates tied to company presentations and diagnostic-development programs.
The company’s SEC record also includes a definitive proxy statement covering annual meeting proposals, director elections and auditor ratification. Other material-event filings describe senior secured credit facilities with subsidiary guarantees, amendments to bylaws affecting shareholder derivative proceedings, and capital-structure terms relevant to Caris’ public-company reporting obligations.
Caris Life Sciences, Inc. reported higher results for the quarter ended June 30, 2026. Total revenue was 263,712 (amounts in thousands), up from 181,398 a year earlier, driven by molecular profiling services of 252,254, while pharma research and development services declined to 11,458.
Costs and operating expenses were 236,786, producing income from operations of 26,926 versus a prior-year operating loss of 17,989. A 25,232 loss on extinguishment of the 2023 term loan and interest expense of 9,228 led to a small net loss of 637 for the quarter and 1,147 year-to-date, compared with 71,790 and 174,370 in 2025.
As of June 30, 2026, Caris held cash, cash equivalents and restricted cash of 692,745 and short-term marketable securities of 102,200, against long-term indebtedness of 392,973. Operating activities provided 61,353 of cash in the first half. The company also authorized a 100.0 million share repurchase program and retired 1,000,000 shares for 17.9 million.
Caris Life Sciences, Inc. reported second quarter 2026 results and raised full-year 2026 revenue guidance to $1.03–$1.04 billion, representing growth of 27%–28% versus 2025.
For the quarter ended June 30, 2026, total revenue was $263.7 million, up 45% year over year, driven by 55% growth in molecular profiling services and approximately 59,200 clinical cases. Gross margin reached 68%, about 500 basis points higher than a year earlier. Net loss was $0.6 million, compared to $71.8 million in the prior-year quarter, and Adjusted EBITDA was $55.7 million.
Operating cash flow was $28.5 million and free cash flow $6.4 million. Cash, cash equivalents and restricted cash totaled 692,745 (amounts in thousands of dollars) at June 30, 2026. The company highlighted launches including Caris Detect and Caris ChromoSeq and a share repurchase program of up to $100 million, with approximately $82.1 million remaining authorized.
Caris Life Sciences director Jon Halbert reported an open-market purchase of 68,000 shares of Common Stock on May 15, 2026, at a weighted average price of $14.56 per share, through LAH Investments, Ltd.. These shares were bought in multiple trades between $14.49 and $14.60 per share. Following this transaction, LAH Investments, Ltd. held 704,598 shares indirectly, a family trust held 637,887 shares indirectly, and Halbert held 118,621 shares directly. Some indirect holdings include shares received in pro rata distributions exempt under Rule 16a-9, and Halbert disclaims beneficial ownership except to the extent of his pecuniary interest.
Caris Life Sciences, Inc. reported results of its 2026 Annual Meeting of Shareholders held on June 4, 2026. Shareholders elected ten directors to serve until the 2027 annual meeting and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
As of the April 9, 2026 record date, 282,662,545 common shares were issued, outstanding and eligible to vote, and 273,714,520 shares were represented at the meeting, constituting a quorum. Each director nominee received more votes for than withheld, and the auditor ratification proposal received substantially more votes for than against or abstaining.
POSTE GEORGE reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director George Poste reported routine equity compensation and a prior ownership reclassification. He received 1,600 shares of common stock as a grant in lieu of cash 2026 board retainer fees, based on a ten-day average price of $15.62 per share. After this award, he holds 17,729 shares directly. A previous transfer of 204,108 shares from direct ownership into a family trust contributed to an indirect total of 511,702 shares, and did not change his overall beneficial ownership.
Knowles Jonathan Kenneth Charles reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Jonathan Kenneth Charles Knowles received 1,600 shares of Common Stock on May 29, 2026 as a stock grant. The shares were issued in lieu of cash compensation for his 2026 board retainer fees, based on a ten-day volume weighted average price calculation. Following this award, he directly owns 308,979 shares of Caris Life Sciences common stock.
Caris Life Sciences executive John Russel Denton reported routine equity compensation activity. On May 15, 2026, 6,047 shares of common stock were withheld at $15.25 per share to cover taxes on the vesting and settlement of RSUs, a non‑market tax-withholding disposition coded "F".
Following this event, Denton directly held 181,515 shares of common stock and indirectly held 9,184 shares through a trust. The filing shows no open-market purchases or sales, indicating a compensation-related adjustment rather than a discretionary trade.
Caris Life Sciences executive Luke Thomas Power used company stock to cover taxes on vested RSUs. On this Form 4, 9,771 shares of Common Stock were withheld at $15.25 per share to pay withholding taxes. After this tax-withholding disposition, he directly holds 153,771 shares.
Caris Life Sciences, Inc. president David Baxley Spetzler reported a routine tax-withholding disposition related to vested RSUs. On the transaction date, 13,856 shares of common stock were withheld at $15.25 per share to cover taxes, leaving him with 530,083 shares owned directly after the transaction.